RxDoctor Payments Data

Heeten Bhoot, DO

Nephrology · Norco, CANPI 1740731413

Payments from drug & device makers

$1,597in general payments, 2019–2025

Across 51 payments — averaging $31.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • C. R. Bard, Inc. & Subsidiaries$372
  • AstraZeneca$346
  • Vifor Pharma, Inc.$224
  • Amgen$148
  • GSK$135
  • Akebia Therapeutics Inc$85
  • plus $286 from 7 others

What the payments were for

  • Consulting fees$37223%
  • Food & beverage$1,16273%
  • Education$634%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,597 in reported general payments places this provider in the 50th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$266,632
Medicare patients
392
Services billed
2,120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol290$202,027
KerendiaFinerenone189$136,174
Tolvaptan52$114,984
LokelmaSodium Zirconium Cyclosilicate134$103,880
ProcritEpoetin Alfa95$74,958
VeltassaPatiromer Calcium Sorbitex71$63,582
AuryxiaFerric Citrate32$43,246
XphozahTenapanor Hcl13$34,727
EliquisApixaban44$28,736
EpogenEpoetin Alfa12$21,463
JardianceEmpagliflozin35$21,197
JanuviaSitagliptin Phosphate21$13,431
ProsolParenteral Amino Acid 20% No.172$10,059
RetacritEpoetin Alfa-Epbx33$7,919
Sevelamer Carbonate53$7,227

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$346$305,906424 claims
BayerKerendia$73$136,174189 claims
Johnson & JohnsonProcrit$19$74,95895 claims
Akebia Therapeutics IncAuryxia$85$43,24632 claims
AmgenEpogen$148$21,46312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,341 nephrology providers in California.

Other nephrology in Norco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →